BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the NSCLC cohort.

Rieke Fischer,Julie George,Andreas H. Scheel,Hans Anton Schloesser,Maria J.G.T. Vehreschild,Peter Brossart,Walburga Engel-Riedel,Frank Griesinger,Christian Grohé,Karl-Otto Kambartel,Jens Kern,Barbara Hermes,Kathrin Nachtkamp,Jens Panse,Martin Sebastian,Markus Lehmann,Rainer Wiewrodt,Reinhard Büttner,Roman K. Thomas,Juergen Wolf

BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the NSCLC cohort.

2019

8563Background: Patient selection, dosing regimens and resistance mechanisms for immune checkpoint inhibitor combination therapy remain unmet medical needs in lung cancer. We present interim data f...

Keywords:

Combination therapy
Nivolumab
Ipilimumab
Cohort
Lung cancer
Dosing
Immune checkpoint
Pathology
Biomarker (medicine)
Oncology
Internal medicine
Medicine
Blockade

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations